Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Manufacturer sponsorship bias in economic analyses matters

Nature Reviews Clinical Oncology volume 9, pages 309–310 (2012)Cite this article

Subjects

A qualitative study indicates that there is a positive selection bias towards favourable economic analysis of targeted therapies, when these are funded by the manufacturer. At a time of increasing budgetary constraints and public scrutiny of the relationship between industry and the professions, we need a more mixed economy of funding for this field.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Campbell, E. G. et al. A national survey of physician–industry relationships. N. Engl. J. Med. 356, 1742–1750 (2007).

    Article  CAS  Google Scholar 

  2. Djulbegovic, B., Angelotta, C., Knox, K. E. & Bennett, C. L. The sound and the fury: financial conflicts of interest in oncology. J. Clin. Oncol. 25, 3567–3569 (2007).

    Article  Google Scholar 

  3. Valachis, A., Polyzos, N. P., Nearchou, A., Lind, P. & Mauri, D. Financial relationships in economic analyses of targeted therapies in oncology. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2011.38.6078.

  4. Jang, S., Chae, Y. K., Haddad, T. & Majhail, N. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res. Treat. 121, 273–279 (2010).

    Article  Google Scholar 

  5. Barbieri, M. & Drummond, M. F. Conflict of interest in industry-sponsored economic evaluations: real or imagined? Curr. Oncol. Rep. 3, 410–413 (2010).

    Article  Google Scholar 

  6. Porter, M. E. in Evidence-based medicine and the changing nature of health care: 2007 Institute of Medicine (IOM) annual meeting summary 1st edn Ch. 14 (eds McClellan, M. B., McGinnis, J. M., Nabel, E. G. & Olsen, L. M.) 161–173 (National Academies Press, Washington DC, 2007).

    Google Scholar 

  7. Sullivan, R. et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 12, 933–980 (2011).

    Article  Google Scholar 

  8. US National Library of Medicine. ClinicalTrials.gov [online], (2012).

Download references

Author information

Authors and Affiliations

  1. Nuffield Department of Clinical and Laboratory Sciences, University of Oxford, Oxford, OX3 7DQ, UK

    David Kerr

  2. Suez Canal University, Borg Alsafwa Centre, 3 Algeish Street, Port Said, 42111, Egypt

    Ahmed Elzawawy

Authors
  1. David Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed Elzawawy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Kerr.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerr, D., Elzawawy, A. Manufacturer sponsorship bias in economic analyses matters. Nat Rev Clin Oncol 9, 309–310 (2012). https://doi.org/10.1038/nrclinonc.2012.75

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.75

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing